CYTOKINETICS, INCORPORATED Payments to Acquire Debt Securities, Available-for-sale
CYTOKINETICS, INCORPORATED (CYTK) reported Payments to Acquire Debt Securities, Available-for-sale of $833.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $727.26M, a 226.18% increase year-over-year.
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $106.52M, a 33.05% decline year-over-year.
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $345.65M, a 185.37% increase year-over-year.
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $335.45M, a 56.46% increase year-over-year.
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.06B, a 17.80% decline from fiscal 2024.
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.29B, a 103.62% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for fiscal 2023 was $635.21M, a 25.74% decline from fiscal 2022.
- CYTOKINETICS, INCORPORATED payments to acquire debt securities, available-for-sale for fiscal 2022 was $855.39M, a 62.92% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 167 month | Payments to Acquire Debt Securities, Available-for-sale 170 month | Payments to Acquire Debt Securities, Available-for-sale 173 month | Payments to Acquire Debt Securities, Available-for-sale 176 month | Payments to Acquire Debt Securities, Available-for-sale 179 month | Payments to Acquire Debt Securities, Available-for-sale 182 month | Payments to Acquire Debt Securities, Available-for-sale 185 month | Payments to Acquire Debt Securities, Available-for-sale 188 month | Payments to Acquire Debt Securities, Available-for-sale 191 month | Payments to Acquire Debt Securities, Available-for-sale 194 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $727.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $833.78M 10-Q · filed 2026-08-06 | $1.18B derived: sum of 3 quarters · filed 2026-08-06 | $1.51B derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2026-03-31 | $106.52M 10-Q · filed 2026-05-05 | $452.17M derived: sum of 2 quarters · filed 2026-05-05 | $787.62M derived: sum of 3 quarters · filed 2026-05-05 | $1.01B derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2025-12-31 | $345.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $681.10M derived: sum of 2 quarters · filed 2026-02-26 | $904.07M derived: sum of 3 quarters · filed 2026-08-06 | $1.06B 10-K · filed 2026-02-26 | ||||||||||
| 2025-09-30 | $335.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $558.42M derived: sum of 2 quarters · filed 2026-08-06 | $717.52M 10-Q · filed 2025-11-05 | $838.65M derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2025-06-30 | $222.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $382.07M 10-Q · filed 2026-08-06 | $503.20M derived: sum of 3 quarters · filed 2026-08-06 | $717.60M derived: sum of 4 quarters · filed 2026-08-06 | ||||||||||
| 2025-03-31 | $159.10M 10-Q · filed 2026-05-05 | $280.23M derived: sum of 2 quarters · filed 2026-05-05 | $494.63M derived: sum of 3 quarters · filed 2026-05-05 | $1.31B derived: sum of 4 quarters · filed 2026-05-05 | ||||||||||
| 2024-12-31 | $121.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $335.53M derived: sum of 2 quarters · filed 2026-02-26 | $1.15B derived: sum of 3 quarters · filed 2026-02-26 | $1.29B 10-K · filed 2026-02-26 | ||||||||||
| 2024-09-30 | $214.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.03B derived: sum of 2 quarters · filed 2025-11-05 | $1.17B 10-Q · filed 2025-11-05 | $1.40B derived: sum of 4 quarters · filed 2026-02-26 | ||||||||||
| 2024-06-30 | $815.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $957.89M 10-Q · filed 2025-08-07 | $1.18B derived: sum of 3 quarters · filed 2026-02-26 | $1.30B derived: sum of 4 quarters · filed 2026-02-26 | ||||||||||
| 2024-03-31 | $142.66M 10-Q · filed 2025-05-06 | $368.77M derived: sum of 2 quarters · filed 2026-02-26 | $486.50M derived: sum of 3 quarters · filed 2026-02-26 | $688.09M derived: sum of 4 quarters · filed 2026-02-26 | ||||||||||
| 2023-12-31 | $226.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $343.84M derived: sum of 2 quarters · filed 2026-02-26 | $545.43M derived: sum of 3 quarters · filed 2026-02-26 | $635.21M 10-K · filed 2026-02-26 | ||||||||||
| 2023-09-30 | $117.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $319.32M derived: sum of 2 quarters · filed 2024-11-07 | $409.10M 10-Q · filed 2024-11-07 | $534.27M derived: sum of 4 quarters · filed 2025-02-27 | ||||||||||
| 2023-06-30 | $201.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $291.37M 10-Q · filed 2024-08-09 | $416.55M derived: sum of 3 quarters · filed 2025-02-27 | $883.73M derived: sum of 4 quarters · filed 2025-02-27 | ||||||||||
| 2023-03-31 | $89.78M 10-Q · filed 2024-05-10 | $214.96M derived: sum of 2 quarters · filed 2025-02-27 | $682.13M derived: sum of 3 quarters · filed 2025-02-27 | $752.04M derived: sum of 4 quarters · filed 2025-02-27 | ||||||||||
| 2022-12-31 | $125.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $592.36M derived: sum of 2 quarters · filed 2025-02-27 | $662.27M derived: sum of 3 quarters · filed 2025-02-27 | $855.39M 10-K · filed 2025-02-27 | ||||||||||
| 2022-09-30 | $467.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $537.09M derived: sum of 2 quarters · filed 2023-11-03 | $730.21M 10-Q · filed 2023-11-03 | $761.81M derived: sum of 4 quarters · filed 2024-02-28 | ||||||||||
| 2022-06-30 | $69.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $263.04M 10-Q · filed 2023-08-03 | $294.63M derived: sum of 3 quarters · filed 2024-02-28 | $616.22M derived: sum of 4 quarters · filed 2024-02-28 | ||||||||||
| 2022-03-31 | $193.13M 10-Q · filed 2023-05-05 | $224.72M derived: sum of 2 quarters · filed 2024-02-28 | $546.31M derived: sum of 3 quarters · filed 2024-02-28 | $651.97M derived: sum of 4 quarters · filed 2024-02-28 | ||||||||||
| 2021-12-31 | $31.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $353.18M derived: sum of 2 quarters · filed 2024-02-28 | $458.84M derived: sum of 3 quarters · filed 2024-02-28 | $525.04M 10-K · filed 2024-02-28 | ||||||||||
| 2021-09-30 | $321.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $427.25M derived: sum of 2 quarters · filed 2022-11-04 | $493.45M 10-Q · filed 2022-11-04 | $762.73M derived: sum of 4 quarters · filed 2023-03-01 | ||||||||||
| 2021-06-30 | $105.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $171.86M 10-Q · filed 2022-08-05 | $441.14M derived: sum of 3 quarters · filed 2023-03-01 | $579.82M derived: sum of 4 quarters · filed 2023-03-01 | ||||||||||
| 2021-03-31 | $66.20M 10-Q · filed 2022-05-06 | $335.48M derived: sum of 2 quarters · filed 2023-03-01 | $474.16M derived: sum of 3 quarters · filed 2023-03-01 | $491.43M derived: sum of 4 quarters · filed 2023-03-01 | ||||||||||
| 2020-12-31 | $269.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $407.96M derived: sum of 2 quarters · filed 2023-03-01 | $425.23M derived: sum of 3 quarters · filed 2023-03-01 | $435.82M 10-K · filed 2023-03-01 | ||||||||||
| 2020-09-30 | $138.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $155.96M derived: sum of 2 quarters · filed 2021-11-05 | $166.55M 10-Q · filed 2021-11-05 | $302.63M derived: sum of 4 quarters · filed 2022-02-25 | ||||||||||
| 2020-06-30 | $17.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $27.87M 10-Q · filed 2021-08-06 | $163.95M derived: sum of 3 quarters · filed 2022-02-25 | $205.59M derived: sum of 4 quarters · filed 2022-02-25 | ||||||||||
| 2020-03-31 | $10.59M 10-Q · filed 2021-05-07 | $146.68M derived: sum of 2 quarters · filed 2022-02-25 | $188.31M derived: sum of 3 quarters · filed 2022-02-25 | $247.18M derived: sum of 4 quarters · filed 2022-02-25 | ||||||||||
| 2019-12-31 | $136.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $177.72M derived: sum of 2 quarters · filed 2022-02-25 | $236.59M derived: sum of 3 quarters · filed 2022-02-25 | $277.88M 10-K · filed 2022-02-25 | ||||||||||
| 2019-09-30 | $41.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $100.50M derived: sum of 2 quarters · filed 2020-11-06 | $141.80M 10-Q · filed 2020-11-06 | $193.59M derived: sum of 4 quarters · filed 2021-02-26 | ||||||||||
| 2019-06-30 | $58.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $100.16M 10-Q · filed 2020-08-07 | $151.96M derived: sum of 3 quarters · filed 2021-02-26 | $208.18M derived: sum of 4 quarters · filed 2021-02-26 | ||||||||||
| 2019-03-31 | $41.30M 10-Q · filed 2020-05-08 | $93.09M derived: sum of 2 quarters · filed 2021-02-26 | $149.31M derived: sum of 3 quarters · filed 2021-02-26 | $257.30M derived: sum of 4 quarters · filed 2021-02-26 | ||||||||||
| 2018-12-31 | $51.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $108.02M derived: sum of 2 quarters · filed 2021-02-26 | $216.00M derived: sum of 3 quarters · filed 2021-02-26 | $240.22M 10-K · filed 2021-02-26 | ||||||||||
| 2018-09-30 | $56.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $164.20M derived: sum of 2 quarters · filed 2019-11-01 | $188.43M 10-Q · filed 2019-11-01 | $214.38M derived: sum of 4 quarters · filed 2019-11-01 | ||||||||||
| 2018-06-30 | $107.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $132.21M 10-Q · filed 2019-08-09 | $158.16M derived: sum of 3 quarters · filed 2019-08-09 | $171.09M derived: sum of 4 quarters · filed 2019-08-09 | ||||||||||
| 2018-03-31 | $24.22M 10-Q · filed 2019-05-09 | $50.18M derived: sum of 2 quarters · filed 2019-05-09 | $63.11M derived: sum of 3 quarters · filed 2019-05-09 | $131.87M derived: sum of 4 quarters · filed 2019-05-09 | ||||||||||
| 2017-12-31 | $25.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $38.88M derived: sum of 2 quarters · filed 2019-03-07 | $107.64M derived: sum of 3 quarters · filed 2019-03-07 | $240.41M 10-K · filed 2019-03-07 | ||||||||||
| 2017-09-30 | $12.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $81.69M derived: sum of 2 quarters · filed 2018-11-09 | $214.46M 10-Q · filed 2018-11-09 | $279.65M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||||
| 2017-06-30 | $68.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $201.53M 10-Q · filed 2018-08-07 | $266.72M derived: sum of 3 quarters · filed 2018-08-07 | $275.98M derived: sum of 4 quarters · filed 2018-08-07 | ||||||||||
| 2017-03-31 | $132.77M 10-Q · filed 2018-05-10 | $197.96M derived: sum of 2 quarters · filed 2018-05-10 | $207.22M derived: sum of 3 quarters · filed 2018-05-10 | $227.78M derived: sum of 4 quarters · filed 2018-05-10 | ||||||||||
| 2016-12-31 | $65.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $74.45M derived: sum of 2 quarters · filed 2018-03-05 | $95.01M derived: sum of 3 quarters · filed 2018-03-05 | $145.16M 10-K · filed 2018-03-05 | ||||||||||
| 2016-09-30 | $9.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $29.82M derived: sum of 2 quarters · filed 2017-11-03 | $79.97M 10-Q · filed 2017-11-03 | $100.88M derived: sum of 4 quarters · filed 2018-03-05 | ||||||||||
| 2016-06-30 | $20.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $70.71M 10-Q · filed 2017-08-04 | $91.62M derived: sum of 3 quarters · filed 2018-03-05 | $120.62M derived: sum of 4 quarters · filed 2018-03-05 | ||||||||||
| 2016-03-31 | $50.15M 10-Q · filed 2017-05-04 | $71.05M derived: sum of 2 quarters · filed 2018-03-05 | $100.06M derived: sum of 3 quarters · filed 2018-03-05 | $115.87M derived: sum of 4 quarters · filed 2018-03-05 | ||||||||||
| 2015-12-31 | $20.91M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-05 | $49.91M derived: sum of 2 quarters · filed 2018-03-05 | $65.73M derived: sum of 3 quarters · filed 2018-03-05 | $115.57M 10-K · filed 2018-03-05 | ||||||||||
| 2015-09-30 | $29.00M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-12-15 | $44.82M derived: sum of 2 quarters · filed 2016-12-15 | $94.66M 10-Q/A · filed 2016-12-15 | $108.46M derived: sum of 4 quarters · filed 2017-03-06 | ||||||||||
| 2015-06-30 | $15.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $65.66M 10-Q · filed 2016-08-04 | $79.45M derived: sum of 3 quarters · filed 2017-03-06 | $85.01M derived: sum of 4 quarters · filed 2017-03-06 | ||||||||||
| 2015-03-31 | $49.84M 10-Q · filed 2016-05-05 | $63.64M derived: sum of 2 quarters · filed 2017-03-06 | $69.20M derived: sum of 3 quarters · filed 2017-03-06 | $101.41M derived: sum of 4 quarters · filed 2017-03-06 | ||||||||||
| 2014-12-31 | $13.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $19.36M derived: sum of 2 quarters · filed 2017-03-06 | $51.57M derived: sum of 3 quarters · filed 2017-03-06 | $107.04M 10-K · filed 2017-03-06 | ||||||||||
| 2014-09-30 | $5.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $37.77M derived: sum of 2 quarters · filed 2015-11-05 | $93.24M 10-Q · filed 2015-11-05 | $104.39M derived: sum of 4 quarters · filed 2016-03-03 | ||||||||||
| 2014-06-30 | $32.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $87.69M 10-Q · filed 2015-08-05 | $98.83M derived: sum of 3 quarters · filed 2016-03-03 | $128.05M derived: sum of 4 quarters · filed 2016-03-03 | ||||||||||
| 2014-03-31 | $55.47M 10-Q · filed 2015-05-04 | $66.62M derived: sum of 2 quarters · filed 2016-03-03 | $95.83M derived: sum of 3 quarters · filed 2016-03-03 | $127.14M derived: sum of 4 quarters · filed 2016-03-03 | ||||||||||
| 2013-12-31 | $11.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $40.37M derived: sum of 2 quarters · filed 2016-03-03 | $71.67M derived: sum of 3 quarters · filed 2016-03-03 | $79.43M 10-K · filed 2016-03-03 | ||||||||||
| 2013-09-30 | $29.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $60.52M derived: sum of 2 quarters · filed 2014-11-06 | $68.29M 10-Q · filed 2014-11-06 | $79.56M derived: sum of 4 quarters · filed 2015-03-06 | $1.12B 10-Q · filed 2013-11-06 | |||||||||
| 2013-06-30 | $31.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $39.07M 10-Q · filed 2014-08-07 | $50.34M derived: sum of 3 quarters · filed 2015-03-06 | $104.97M derived: sum of 4 quarters · filed 2015-03-06 | $1.09B 10-Q · filed 2013-08-07 | |||||||||
| 2013-03-31 | $7.76M 10-Q · filed 2014-05-07 | $19.04M derived: sum of 2 quarters · filed 2015-03-06 | $73.66M derived: sum of 3 quarters · filed 2015-03-06 | $89.80M derived: sum of 4 quarters · filed 2015-03-06 | $1.06B 10-Q · filed 2013-05-08 | |||||||||
| 2012-12-31 | $11.28M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-06 | $65.90M derived: sum of 2 quarters · filed 2015-03-06 | $82.04M derived: sum of 3 quarters · filed 2015-03-06 | $92.79M 10-K · filed 2015-03-06 | $1.05B 10-K · filed 2013-03-15 | |||||||||
| 2012-09-30 | $54.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $70.77M derived: sum of 2 quarters · filed 2013-11-06 | $81.51M 10-Q · filed 2013-11-06 | $88.66M derived: sum of 4 quarters · filed 2014-03-07 | $1.04B 10-Q · filed 2012-11-07 | |||||||||
| 2012-06-30 | $16.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $26.89M 10-Q · filed 2013-08-07 | $34.04M derived: sum of 3 quarters · filed 2014-03-07 | $49.77M derived: sum of 4 quarters · filed 2014-03-07 | $986.34M 10-Q · filed 2012-08-06 | |||||||||
| 2012-03-31 | $10.75M 10-Q · filed 2013-05-08 | $17.90M derived: sum of 2 quarters · filed 2014-03-07 | $33.63M derived: sum of 3 quarters · filed 2014-03-07 | $51.65M derived: sum of 4 quarters · filed 2014-03-07 | $970.20M 10-Q · filed 2012-05-04 | |||||||||
| 2011-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $22.89M derived: sum of 2 quarters · filed 2014-03-07 | $40.90M derived: sum of 3 quarters · filed 2014-03-07 | $48.02M 10-K · filed 2014-03-07 | $959.46M 10-K · filed 2012-03-13 | |||||||||
| 2011-09-30 | $15.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $33.75M derived: sum of 2 quarters · filed 2012-11-07 | $40.88M 10-Q · filed 2012-11-07 | $68.95M derived: sum of 4 quarters · filed 2013-03-15 | $952.31M 10-Q · filed 2011-11-04 | |||||||||
| 2011-06-30 | $18.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-06 | $25.14M 10-Q · filed 2012-08-06 | $53.21M derived: sum of 3 quarters · filed 2013-03-15 | $68.45M derived: sum of 4 quarters · filed 2013-03-15 | $936.57M 10-Q · filed 2011-08-04 | |||||||||
| 2011-03-31 | $7.12M 10-Q · filed 2012-05-04 | $35.19M derived: sum of 2 quarters · filed 2013-03-15 | $50.44M derived: sum of 3 quarters · filed 2013-03-15 | |||||||||||
| 2010-12-31 | $28.07M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $43.32M derived: sum of 2 quarters · filed 2013-03-15 | $109.86M 10-K · filed 2013-03-15 | |||||||||||
| 2010-09-30 | $15.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $81.79M 10-Q · filed 2011-11-04 | ||||||||||||
| 2010-06-30 | $66.54M 10-Q · filed 2011-08-04 | |||||||||||||
| 2009-12-31 | $132.21M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |